Displaying items 141-143 of 143 in total
As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.
After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.
A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.
Get your daily brief delivered to your inbox every morning at 7am
